collected and the concentration of TNF-a and IL-12p70 was analyzed. As depicted in Table 1 , 8 of 10 primary AML cell samples did not alter the secretion of TNF-a and IL-12 by activated slanDCs. Interestingly, two AML cell samples significantly impair the capability of activated slanDCs to produce these cytokines. The evaluated AML cell samples did not secrete TNF-a and IL-12 under these conditions as determined by flow cytometry (data not shown).
In summary, we showed that none of the 10 evaluated AML cell samples induces the secretion of the cytotoxic effector molecule TNF-a or the immunomodulatory cytokine IL-12 in unstimulated slanDCs. The failure to trigger slanDC activation efficiently can be explained by an insufficient expression of 'danger' molecules by AML cells and/or the production of inhibitory molecules. As a consequence, the capacity of slanDCs to mediate tumor-directed cytotoxicity 7 and to activate tumor-reactive NK cells 8 and T cells 6 may be impaired. In addition, we found that two AML cell samples significantly inhibit TNF-a and IL-12 secretion by activated slanDCs. Besides the potential of primary AML cells to evade the control of NK cells and T cells, [2] [3] [4] their failure to trigger unstimulated native human DCs as well as their capability to inhibit the cytokine production of activated DCs may represent additional immune escape mechanisms. These various mechanisms may be important in the development and relapse of AML despite immunosurveillance. In addition, they may also have implications for the design of immunotherapeutic strategies for AML.
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The authors declare no conflict of interest. Multiple myeloma (MM) is characterized by an increase of bone marrow (BM) angiogenesis that occurs in close contact with plasma cells accumulation. 1, 2 Hypoxia is associated to angiogenesis in solid tumors and hypoxia-inducible factor (HIF)-1a is a critical trigger and regulator of the angiogenic switch. 3, 4 It is known that the BM microenvironment is hypoxic in healthy subjects, 5 however, the BM oxygen levels in patients with MM have never been investigated and the effects of hypoxia and its main transcription factor HIF-1a on the transcriptional and proangiogenic profiles of CD138 þ cells are not known.
In this study, we investigated BM oxygen partial pressure (pO 2 ) and saturation (sO 2 ) by aspiration of 2 ml of marrow samples immediately analyzed by a gas analyzer (ABL800 FLEX Radiometer, Copenhagen, Denmark) in a cohort of 44 patients, including symptomatic MM (n ¼ 25), smoldering MM (n ¼ 8) and Monoclonal Gammopathy of Undetermined Significance (n ¼ 11). Six healthy subjects without any pathological BM involvement were also investigated. Protocol was approved by our local ethic committee. We show that BM of MM patients was hypoxic, even if any significant difference in both pO 2 and sO 2 was not observed in comparison with smoldering MM patients, Monocolonal Gammopathy of Undetermined Significane or healthy subjects, and in relationship with the stage of MM disease (P ¼ 0.6; Figure 1a ). Accordingly, we did not find any significant difference in the messenger RNA (mRNA) expression of HIF-1a target genes (AK3 and BNIP3) in CD138 þ samples from Monocolonal Gammopathy of Undetermined Significane and MM cases (data not shown) similar to what was previously observed for the expression of VEGFA mRNA in MM cells by others. 6, 7 The median pO 2 and sO 2 values measured in MM BM samples of our cohort of patients and controls were analogous to those reported in healthy volunteers. 5 However, in an MM mouse model, it has been recently reported that both normal and MM-infiltrated BM are hypoxic, although the level of hypoxia was lower in MM BM. 8 The discrepancy between our data and those obtained in mice could be due in part to the different method used by Asosingh et al. 8 in the detection of hypoxia, based on pimonidazole hypoxyprobe binding, but also to the lower physiological oxygen tension reported in mice 8,9 as compared to human BM microenvironment. 5 Next, we evaluated how hypoxic treatment with the hypoxic mimetic drug CoCl 2 at 100 mM (Sigma Aldrich, St Louis, MO, USA) modified the transcriptional profile of CD138 þ cells isolated form MM patients by U133 Plus2.0 Arrays GeneChip (Affymetrix, Santa Clara, CA, USA). By supervised analysis performed on 11 paired MM samples we observed that hypoxia significantly modulated 714 genes in CD138 þ cells isolated from MM patients. Interestingly, genes belonging either to oxidative stress and hypoxia signaling, including heme oxygenase 1 (HMOX1) and the heat-shock protein 90 kDa alpha (HSP90AA1; HSP90AB1), or to protein ubiquitination pathway, such as XIAP, were significantly upregulated by hypoxia. Among the proangiogenic genes, we observed that both VEGFA and IL8 were induced by hypoxia (Table 1, panel i and Supplementary  Table 1 Given that HIF-1a accumulates only in hypoxic condition, we checked HIF-1a protein expression in the BM of MM patients by immunohistochemistry on bone biopsies with mouse anti-HIF-1a monoclonal antibody (NOVUS Biologicals Littleton, CO, USA; working dilution 1:100). A strong HIF-1a immunostaining was demonstrated in MM cells at nuclear level in all patients analyzed with a diffuse pattern of expression consistently with the pO 2 levels measured (Figure 1b) similarly to that observed in other tumors as in lymphoma-infiltrated lymphonodes. 10 Interestingly, the presence of HIF-1a protein was also observed in isolated CD138
þ MM cells of about 28% of MM patients in normoxic condition (data not shown), indicating that a hypoxia-independent stabilization of HIF-1a may also occur in MM cells as previously reported. 11 Finally, we performed HIF-1a silencing in MM cells using the human myeloma cell lines JJN3 and RPMI-8226 line by small interfering RNA anti-HIF-1a exposing the cells to normoxic or hypoxic conditions. We observed that HIF-1a suppression in hypoxic condition was associated with the downregulation of proangiogenic molecules (VEGFA, VEGFB, TGFB1, PGF), oxidative stress (SOD2, PTGS2, TXT) and glycogenolysis regulators (ENO2, ALDOC, PFKFB3, HK2, PDK1, PFKFB4) and transcription factor genes (MAF, IRF4, JUN, and NFKB2) ( Table 1 panel ii and Supplementary Table 2 ).
In addition, by matching the transcripts resulting as differentially expressed in JJN3 under hypoxic condition, in the presence (Supplementary Table 3 ) or absence (Supplementary  Table 4 ) of HIF-1a silencing, 463 genes were identified as specifically regulated by HIF-1a in hypoxia (in red in Supplementary Table 3 ), whereas 734 genes showed an altered expression in hypoxic condition even in the absence of HIF-1a suppression (in red in Supplementary Table 4) . Among the genes resulting as specifically regulated by HIF-1a, we recognized VEGFA, TGFb, PGF, IGFB3, SOD2, CADM1, BNIP3L and CCL5, whereas HMOX1 gene, strongly induced by hypoxia in MM cells (Supplementary Table 1) , and the angiogenic molecule HGF, upregulated by hypoxia in JJN3 (Supplementary  Table 4 , in red), were not significantly modulated by HIF-1a suppression.
Data obtained were than validated by real-time PCR, western blot and enzyme-linked immunosorbent assay for the proangiogenic molecules (Supplementary Figure 1) . Consistent with these observations, we observed that HIF-1a suppression significantly inhibited the proangiogenic properties, evaluated by an in vitro angiogenesis model (Angio Kit, TCS Biologicals; Buckingham, UK; Figure 1c ). All these evidences strongly support the idea that HIF-1a is a potential target of anti-angiogenic therapy in MM. In such context, it has been recently reported that adaphostin inhibits HIF-1a expression showing a significant anti-angiogenic and anti-MM activity in an MM xenograft mouse model. 11 In addition, it has been also reported that the inhibitory effect of the proteasome inhibitor Bortezomib on tumor angiogenesis involves the repression of HIF-1a transcriptional activity 12 and that lenalidomide inhibits HIF-1a protein expression in endothelial cells. 13 In conclusion, we demonstrate that MM-BM environment is hypoxic, HIF-1a protein is highly expressed by MM cells and it modulates the transcriptional and proangiogenic profiles of MM cells and their proangiogenic properties, suggesting that HIF-1a is involved in MM-induced angiogenesis and it could be a potential therapeutic target in MM patients.
